EA200870233A1 - Производные тиадиазола для лечения нейродегенеративных заболеваний - Google Patents

Производные тиадиазола для лечения нейродегенеративных заболеваний

Info

Publication number
EA200870233A1
EA200870233A1 EA200870233A EA200870233A EA200870233A1 EA 200870233 A1 EA200870233 A1 EA 200870233A1 EA 200870233 A EA200870233 A EA 200870233A EA 200870233 A EA200870233 A EA 200870233A EA 200870233 A1 EA200870233 A1 EA 200870233A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
treatment
derivatives
tiadiazole
neurodegenerative diseases
Prior art date
Application number
EA200870233A
Other languages
English (en)
Other versions
EA018067B1 (ru
Inventor
Герард Гриффиун
Кристель Мари Эдит Купе
Хейн Роже Дюамель
Стефан Вера
Эллен Гомме
Неле Ван Дамм
Ингрид Ван Дер Аувера
Марлен Локс
Том Ван Дорен
Тине Декрей
Original Assignee
Нв Реминд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нв Реминд filed Critical Нв Реминд
Publication of EA200870233A1 publication Critical patent/EA200870233A1/ru
Publication of EA018067B1 publication Critical patent/EA018067B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение предусматривает специфические замещенные производные 1,2,4-тиадиазола для применения при лечении α-синуклеинопатий, таких как болезнь Паркинсона, диффузионная болезнь телец Леви, травматическое повреждение мозга, боковой амиотрофический склероз, болезнь Неймана-Пикка, синдром Галлервордена-Спатца, синдром Дауна, нейроаксональная дистрофия, множественная системная атрофия и болезнь Альцгеймера.
EA200870233A 2006-02-07 2007-02-07 Производные тиадиазола для лечения нейродегенеративных заболеваний EA018067B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0602335.2A GB0602335D0 (en) 2006-02-07 2006-02-07 Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
PCT/EP2007/001022 WO2007090617A2 (en) 2006-02-07 2007-02-07 Thiadiazole derivatives for the treatment of neuro degenerative diseases

Publications (2)

Publication Number Publication Date
EA200870233A1 true EA200870233A1 (ru) 2009-02-27
EA018067B1 EA018067B1 (ru) 2013-05-30

Family

ID=36101115

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870233A EA018067B1 (ru) 2006-02-07 2007-02-07 Производные тиадиазола для лечения нейродегенеративных заболеваний

Country Status (16)

Country Link
EP (1) EP1981504B1 (ru)
JP (1) JP5283511B2 (ru)
CN (1) CN101378757B (ru)
AT (1) ATE474579T1 (ru)
AU (1) AU2007213954B2 (ru)
BR (1) BRPI0707700B8 (ru)
CA (1) CA2641453C (ru)
DE (1) DE602007007890D1 (ru)
DK (1) DK1981504T3 (ru)
EA (1) EA018067B1 (ru)
ES (1) ES2348999T3 (ru)
GB (1) GB0602335D0 (ru)
HK (1) HK1122989A1 (ru)
PL (1) PL1981504T3 (ru)
PT (1) PT1981504E (ru)
WO (1) WO2007090617A2 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008225766B2 (en) 2007-03-15 2012-06-07 Novartis Ag Organic compounds and their uses
WO2009143404A1 (en) * 2008-05-23 2009-11-26 Wyeth Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression
BRPI0914536A8 (pt) * 2008-06-27 2017-05-16 Bayer Cropscience Ag Tiadiazoliloxifenilamidinas, processo para sua preparação e seus usos, composição e processo para combater microorganismos indesejáveis, e semente resistente a microorganismos indesejáveis
KR101712684B1 (ko) 2009-05-04 2017-03-06 바스프 코포레이션 희박 연소 가솔린 엔진을 위한 ｔｗｃ의 개선된 희박 ｈｃ 전환
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
EP2726470B1 (en) * 2011-07-01 2015-04-29 reMynd NV 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases
CA2841037C (en) 2011-08-17 2020-03-31 Remynd Nv Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CN105829310B (zh) 2013-12-20 2019-04-12 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
EP3119774A1 (en) * 2014-03-17 2017-01-25 reMynd NV Oxadiazole compounds
JP7178831B2 (ja) 2018-08-30 2022-11-28 日本特殊陶業株式会社 基板保持部材

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060472A (en) 1998-04-06 2000-05-09 Apotex Inc. Thiadiazole compounds useful as inhibitors of H+ /K+ atpase
US6699866B2 (en) * 2001-04-17 2004-03-02 Sepracor Inc. Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof
EP1658072A4 (en) * 2003-08-21 2009-03-25 Pfizer Prod Inc Compounds for the Treatment of Neurodegenerative Diseases
US7232820B2 (en) * 2004-04-01 2007-06-19 Pfizer Inc Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
DE102004032567A1 (de) * 2004-07-05 2006-03-02 Grünenthal GmbH Substituierte 1-Propiolyl-piperazine

Also Published As

Publication number Publication date
PL1981504T3 (pl) 2010-12-31
DE602007007890D1 (de) 2010-09-02
WO2007090617A3 (en) 2008-02-28
HK1122989A1 (en) 2009-06-05
GB0602335D0 (en) 2006-03-15
EP1981504A2 (en) 2008-10-22
CN101378757B (zh) 2012-08-01
JP2009526000A (ja) 2009-07-16
CN101378757A (zh) 2009-03-04
WO2007090617A2 (en) 2007-08-16
EA018067B1 (ru) 2013-05-30
JP5283511B2 (ja) 2013-09-04
BRPI0707700A2 (pt) 2011-05-10
AU2007213954B2 (en) 2011-09-22
ES2348999T3 (es) 2010-12-21
EP1981504B1 (en) 2010-07-21
BRPI0707700B8 (pt) 2022-12-20
CA2641453C (en) 2013-07-30
BRPI0707700B1 (pt) 2020-08-04
ATE474579T1 (de) 2010-08-15
AU2007213954A1 (en) 2007-08-16
PT1981504E (pt) 2010-10-13
DK1981504T3 (da) 2010-11-08
CA2641453A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
EA200870233A1 (ru) Производные тиадиазола для лечения нейродегенеративных заболеваний
BRPI0818799A2 (pt) Composições para o tratamento da doença de parkinson
EP1986639A4 (en) PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
ZA200802762B (en) Pharmaceutical compositions for the treatment of inner ear disorders
ES2616789T8 (es) Inhibidores de tirosina cinasa de Bruton
EP2037739A4 (en) POSITIVE ALLOSTERIC EFFECTORS OF BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR
IL187904A (en) Use of quinoline derivatives for the preparation of bacterial preparations for the treatment of bacteria caused by bacteria
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MY150558A (en) A pharmaceutical composition comprising rebamipide
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
HK1124863A1 (en) Inhibitors of sodium glucose co-transporter 2 and methods of their use
TN2010000155A1 (en) Organic compounds
WO2009019295A3 (en) Phenyl- and benzylthiazolylpiperazine derivatives for the treatment of neurodegenerative diseases
MX2010013451A (es) Composiciones farmaceuticas que comprenden derivados de aminociclohexano.
NL1033562A1 (nl) Tetrahydropyridoazepine-8-onen en verwante verbindingen voor de behandeling van schizofrenie.
MX340564B (es) Isoformas de neurregulina solubles activas modificadas post-traduccionalmente.
WO2010000089A8 (en) Stat3 and tyk2 as drug targets for neurodegenerative diseases
WO2007017146A3 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors
DE502007002949D1 (de) Proteinbindende methotrexat-derivate und diese enthaltende arzneimittel
WO2009134668A3 (en) 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators
ATE450273T1 (de) Proliferationshemmendes arzneimittel
WO2022204362A3 (en) Compositions and methods for treating a neurodegenerative or developmental disorder
FR2918281B1 (fr) Medicament pour le traitement de la maladie de parkinson.
WO2008014232A3 (en) Pharmaceutical formulations for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM